77 related articles for article (PubMed ID: 19257827)
1. Activin A enhances prostate cancer cell migration through activation of androgen receptor and is overexpressed in metastatic prostate cancer.
Kang HY; Huang HY; Hsieh CY; Li CF; Shyr CR; Tsai MY; Chang C; Chuang YC; Huang KE
J Bone Miner Res; 2009 Jul; 24(7):1180-93. PubMed ID: 19257827
[TBL] [Abstract][Full Text] [Related]
2. SMAD3 promotes expression and activity of the androgen receptor in prostate cancer.
Jeon HY; Pornour M; Ryu H; Khadka S; Xu R; Jang J; Li D; Chen H; Hussain A; Fazli L; Gleave M; Dong X; Huang F; Wang Q; Barbieri C; Qi J
Nucleic Acids Res; 2023 Apr; 51(6):2655-2670. PubMed ID: 36727462
[TBL] [Abstract][Full Text] [Related]
3. Rat Prostate Tumor Cells Progress in the Bone Microenvironment to a Highly Aggressive Phenotype.
Bergström SH; Rudolfsson SH; Bergh A
Neoplasia; 2016 Mar; 18(3):152-61. PubMed ID: 26992916
[TBL] [Abstract][Full Text] [Related]
4. The Homeobox gene, HOXB13, Regulates a Mitotic Protein-Kinase Interaction Network in Metastatic Prostate Cancers.
Yao J; Chen Y; Nguyen DT; Thompson ZJ; Eroshkin AM; Nerlakanti N; Patel AK; Agarwal N; Teer JK; Dhillon J; Coppola D; Zhang J; Perera R; Kim Y; Mahajan K
Sci Rep; 2019 Jul; 9(1):9715. PubMed ID: 31273254
[TBL] [Abstract][Full Text] [Related]
5. Autophagy provides a conceptual therapeutic framework for bone metastasis from prostate cancer.
Wang Y; Wu N; Jiang N
Cell Death Dis; 2021 Oct; 12(10):909. PubMed ID: 34611139
[TBL] [Abstract][Full Text] [Related]
6. Label-free discrimination of tumorigenesis stages using in vitro prostate cancer bone metastasis model by Raman imaging.
Kar S; Jaswandkar SV; Katti KS; Kang JW; So PTC; Paulmurugan R; Liepmann D; Venkatesan R; Katti DR
Sci Rep; 2022 May; 12(1):8050. PubMed ID: 35577856
[TBL] [Abstract][Full Text] [Related]
7. Non-Canonical Activin A Signaling Stimulates Context-Dependent and Cellular-Specific Outcomes in CRC to Promote Tumor Cell Migration and Immune Tolerance.
Wiley MB; Bauer J; Mehrotra K; Zessner-Spitzenberg J; Kolics Z; Cheng W; Castellanos K; Nash MG; Gui X; Kone L; Maker AV; Qiao G; Reddi D; Church DN; Kerr RS; Kerr DJ; Grippo PJ; Jung B
Cancers (Basel); 2023 May; 15(11):. PubMed ID: 37296966
[TBL] [Abstract][Full Text] [Related]
8. Macrophages and bone metastasis.
Di Mitri D; Conforti F; Mantovani A
J Exp Med; 2023 Apr; 220(4):. PubMed ID: 36828392
[TBL] [Abstract][Full Text] [Related]
9. AR loss in prostate cancer stroma mediated by NF-κB and p38-MAPK signaling disrupts stromal morphogen production.
Tahsin S; Sane NS; Cernyar B; Jiang L; Zohar Y; Lee BR; Miranti CK
Oncogene; 2024 May; ():. PubMed ID: 38769192
[TBL] [Abstract][Full Text] [Related]
10. INHBA is Enriched in HPV-negative Oropharyngeal Squamous Cell Carcinoma and Promotes Cancer Progression.
Abou Kors T; Hofmann L; Betzler A; Payer K; Bens M; Truong J; von Witzleben A; Thomas J; Kraus JM; Kalaajieh R; Huber D; Ezić J; Benckendorff J; Greve J; Schuler PJ; Ottensmeier CH; Kestler HA; Hoffmann TK; Theodoraki MN; Brunner C; Laban S
Cancer Res Commun; 2024 Feb; 4(2):571-587. PubMed ID: 38329386
[TBL] [Abstract][Full Text] [Related]
11. Targeting benign prostate hyperplasia treatments: AR/TGF-β/NOX4 inhibition by apocynin suppresses inflammation and proliferation.
Jin BR; Kim HJ; Na JH; Lee WK; An HJ
J Adv Res; 2024 Mar; 57():135-147. PubMed ID: 37061215
[TBL] [Abstract][Full Text] [Related]
12. Activin B and Activin C Have Opposing Effects on Prostate Cancer Progression and Cell Growth.
Reader KL; John-McHaffie S; Zellhuber-McMillan S; Jowett T; Mottershead DG; Cunliffe HE; Gold EJ
Cancers (Basel); 2022 Dec; 15(1):. PubMed ID: 36612143
[TBL] [Abstract][Full Text] [Related]
13. TGFB1/INHBA Homodimer/Nodal-SMAD2/3 Signaling Network: A Pivotal Molecular Target in PDAC Treatment.
Abdel Mouti M; Pauklin S
Mol Ther; 2021 Mar; 29(3):920-936. PubMed ID: 33429081
[TBL] [Abstract][Full Text] [Related]
14. The use of zebrafish model in prostate cancer therapeutic development and discovery.
Amawi H; Aljabali AAA; Boddu SHS; Amawi S; Obeid MA; Ashby CR; Tiwari AK
Cancer Chemother Pharmacol; 2021 Mar; 87(3):311-325. PubMed ID: 33392639
[TBL] [Abstract][Full Text] [Related]
15. A Positive Feedback Loop Between TGFβ and Androgen Receptor Supports Triple-negative Breast Cancer Anoikis Resistance.
Rosas E; Roberts JT; O'Neill KI; Christenson JL; Williams MM; Hanamura T; Spoelstra NS; Vahrenkamp JM; Gertz J; Richer JK
Endocrinology; 2021 Feb; 162(2):. PubMed ID: 33294922
[TBL] [Abstract][Full Text] [Related]
16. SIRT7 depletion inhibits cell proliferation and androgen-induced autophagy by suppressing the AR signaling in prostate cancer.
Ding M; Jiang CY; Zhang Y; Zhao J; Han BM; Xia SJ
J Exp Clin Cancer Res; 2020 Feb; 39(1):28. PubMed ID: 32019578
[TBL] [Abstract][Full Text] [Related]
17. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
18. ActivinA: a new leukemia-promoting factor conferring migratory advantage to B-cell precursor-acute lymphoblastic leukemic cells.
Portale F; Cricrì G; Bresolin S; Lupi M; Gaspari S; Silvestri D; Russo B; Marino N; Ubezio P; Pagni F; Vergani P; Kronnie GT; Valsecchi MG; Locatelli F; Rizzari C; Biondi A; Dander E; D'Amico G
Haematologica; 2019 Mar; 104(3):533-545. PubMed ID: 30262563
[TBL] [Abstract][Full Text] [Related]
19. Activin-A signaling promotes epithelial-mesenchymal transition, invasion, and metastatic growth of breast cancer.
Bashir M; Damineni S; Mukherjee G; Kondaiah P
NPJ Breast Cancer; 2015; 1():15007. PubMed ID: 28721365
[TBL] [Abstract][Full Text] [Related]
20. Over-Expression of Activin-β
Ottley EC; Reader KL; Lee K; Marino FE; Nicholson HD; Risbridger GP; Gold E
Horm Cancer; 2017 Apr; 8(2):100-107. PubMed ID: 28116672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
